Imcyse is a biotech company based in Liège and Leuven, Belgium, that was created in 2010 as a spin-off of the Catholic University of Leuven (KULeuven). Imcyse research team has developed an extended expertise during over 20 years of academic research. Numerous proof of concept results have been generated in animal models for type 1 diabetes, multiple sclerosis, myasthenia gravis, allergic diseases, prevention of graft rejection, tumor rejection and blocking of immunogenicity to allofactors and viral vectors. Imcyse technology and results are protected by a broad and solid intellectual property portfolio.
In 2015 Imcyse embraced a strategic change towards development and valorization with the recruitment of an experienced management team. Two projects , in Type 1 diabetes and in multiple sclerosis, will soon reach clinical stage.